• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Low-cost alternatives for the management of acute ischemic stroke in low and middle-income countries.低收入和中等收入国家急性缺血性卒中管理的低成本替代方案。
Ann Med Surg (Lond). 2021 Oct 21;72:102969. doi: 10.1016/j.amsu.2021.102969. eCollection 2021 Dec.
2
Early Recanalization Among Patients Undergoing Bridging Therapy With Tenecteplase or Alteplase.替奈普酶或阿替普酶桥接治疗患者的早期再通。
Stroke. 2023 Oct;54(10):2491-2499. doi: 10.1161/STROKEAHA.123.042691. Epub 2023 Aug 25.
3
Safety and efficacy of low-cost alternative urokinase in acute ischemic stroke: A systematic review and meta-analysis.低成本替代尿激酶治疗急性缺血性脑卒中的安全性和有效性:系统评价和荟萃分析。
J Clin Neurosci. 2022 Dec;106:103-109. doi: 10.1016/j.jocn.2022.09.015. Epub 2022 Oct 20.
4
Cost-effectiveness of thrombectomy alone versus alteplase before thrombectomy in acute ischemic stroke: results from the DIRECT-MT.直接机械取栓治疗急性缺血性脑卒中:单纯取栓与取栓前溶栓的成本效果分析——DIRECT-MT 研究结果
J Neurosurg. 2023 Feb 10;139(3):678-686. doi: 10.3171/2022.12.JNS221791. Print 2023 Sep 1.
5
Stroke Center Certification卒中中心认证
6
Cost Effectiveness of Interhospital Transfer for Mechanical Thrombectomy of Acute Large Vessel Occlusion Stroke: Role of Predicted Recanalization Rates.急性大血管闭塞性卒中机械取栓的院间转运的成本效益:预测再通率的作用。
Circ Cardiovasc Qual Outcomes. 2021 Apr;14(4):e007444. doi: 10.1161/CIRCOUTCOMES.120.007444. Epub 2021 Apr 5.
7
Advances in the management of acute ischemic stroke.急性缺血性脑卒中的治疗进展。
Curr Opin Neurol. 2023 Apr 1;36(2):147-154. doi: 10.1097/WCO.0000000000001136. Epub 2023 Feb 7.
8
Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke.替奈普酶静脉溶栓治疗急性缺血性脑卒中。
Ann Neurol. 2022 Sep;92(3):349-357. doi: 10.1002/ana.26445. Epub 2022 Jul 7.
9
European Stroke Organisation (ESO)-European Society for Minimally Invasive Neurological Therapy (ESMINT) expedited recommendation on indication for intravenous thrombolysis before mechanical thrombectomy in patients with acute ischemic stroke and anterior circulation large vessel occlusion.欧洲卒中组织(ESO)-欧洲微创神经治疗学会(ESMINT)关于急性缺血性脑卒中前循环大血管闭塞患者机械取栓前静脉溶栓适应证的快速推荐意见。
J Neurointerv Surg. 2022 Mar;14(3):209. doi: 10.1136/neurintsurg-2021-018589. Epub 2022 Feb 3.
10
Combined Intravenous Thrombolysis and Thrombectomy vs Thrombectomy Alone for Acute Ischemic Stroke: A Pooled Analysis of the SWIFT and STAR Studies.联合静脉溶栓与血管内取栓治疗与单纯血管内取栓治疗急性缺血性脑卒中的对比:SWIFT 和 STAR 研究的汇总分析。
JAMA Neurol. 2017 Mar 1;74(3):268-274. doi: 10.1001/jamaneurol.2016.5374.

引用本文的文献

1
Quantitative Evaluation of Postural SmartVest's Multisensory Feedback for Affordable Smartphone-Based Post-Stroke Motor Rehabilitation.基于经济实惠的智能手机的中风后运动康复中姿势智能背心多感官反馈的定量评估
Int J Environ Res Public Health. 2025 Jun 28;22(7):1034. doi: 10.3390/ijerph22071034.
2
Global, Regional, and National Burden of Cardiovascular Diseases Associated with Particulate Matter Pollution: A Systematic Analysis of Deaths and Disability-Adjusted Life Years with Projections to 2030.与颗粒物污染相关的心血管疾病的全球、区域和国家负担:对死亡和伤残调整生命年的系统分析及到2030年的预测
Rev Cardiovasc Med. 2025 Apr 17;26(4):27056. doi: 10.31083/RCM27056. eCollection 2025 Apr.
3
Wearable Smartphone-Based Multisensory Feedback System for Torso Posture Correction: Iterative Design and Within-Subjects Study.基于可穿戴智能手机的躯干姿势矫正多感官反馈系统:迭代设计与受试者内研究
JMIR Aging. 2025 Jan 22;8:e55455. doi: 10.2196/55455.
4
Global Insights on Prehospital Stroke Care: A Comprehensive Review of Challenges and Solutions in Low- and Middle-Income Countries.全球院前卒中护理洞察:低收入和中等收入国家挑战与解决方案的全面综述
J Clin Med. 2024 Aug 14;13(16):4780. doi: 10.3390/jcm13164780.
5
Cost-effectiveness of tenecteplase versus alteplase for acute ischemic stroke.替奈普酶与阿替普酶治疗急性缺血性脑卒中的成本效果分析。
Eur Stroke J. 2023 Sep;8(3):638-646. doi: 10.1177/23969873231174943. Epub 2023 May 19.
6
Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.药物经济学研究的障碍和促进因素:来自中东国家的证据综述。
Int J Environ Res Public Health. 2022 Jun 27;19(13):7862. doi: 10.3390/ijerph19137862.
7
An opportunity to improve Acute Ischemic Stroke care in the South Asian region through telestroke services.通过远程卒中服务改善南亚地区急性缺血性卒中护理的机会。
Ann Med Surg (Lond). 2021 Nov 25;72:103115. doi: 10.1016/j.amsu.2021.103115. eCollection 2021 Dec.

本文引用的文献

1
Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam.越南一家卒中中心的经验:急性缺血性卒中患者桥接治疗中低剂量与标准剂量静脉注射阿替普酶的对比
Front Neurol. 2021 Apr 9;12:653820. doi: 10.3389/fneur.2021.653820. eCollection 2021.
2
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.急性缺血性脑卒中患者早期管理指南:2018 年急性缺血性脑卒中早期管理指南的更新:美国心脏协会/美国卒中协会发布的医疗保健专业人员指南。
Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
3
Minimal Setting Stroke Unit in a Sub-Saharan African Public Hospital.撒哈拉以南非洲公立医院的极简式卒中单元
Front Neurol. 2019 Aug 7;10:856. doi: 10.3389/fneur.2019.00856. eCollection 2019.
4
Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke: Meta-Analysis of 5 Randomized Trials.替奈普酶与阿替普酶治疗急性缺血性脑卒中非劣效性的证据:5 项随机试验的荟萃分析。
Stroke. 2019 Aug;50(8):2156-2162. doi: 10.1161/STROKEAHA.119.025080. Epub 2019 Jul 18.
5
Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal.尼泊尔急性缺血性脑卒中患者的院前延误和静脉溶栓治疗现状。
BMC Neurol. 2019 Jul 9;19(1):155. doi: 10.1186/s12883-019-1378-3.
6
Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.全球、区域和国家卒中负担,1990-2016 年:2016 年全球疾病负担研究的系统分析。
Lancet Neurol. 2019 May;18(5):439-458. doi: 10.1016/S1474-4422(19)30034-1. Epub 2019 Mar 11.
7
Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials.替奈普酶与阿替普酶治疗急性缺血性脑卒中的比较:随机临床试验的成对和网络荟萃分析。
J Thromb Thrombolysis. 2018 Nov;46(4):440-450. doi: 10.1007/s11239-018-1721-3.
8
Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis.替奈普酶与阿替普酶治疗急性缺血性脑卒中的系统评价和荟萃分析。
Acta Neurol Belg. 2019 Sep;119(3):359-367. doi: 10.1007/s13760-018-0933-9. Epub 2018 May 4.
9
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.替奈普酶与阿替普酶在缺血性脑卒中取栓前的比较。
N Engl J Med. 2018 Apr 26;378(17):1573-1582. doi: 10.1056/NEJMoa1716405.
10
Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study.急性缺血性卒中桥接治疗中低剂量与标准剂量静脉注射阿替普酶的比较:一项韩国ENCHANTED研究
J Stroke. 2018 Jan;20(1):131-139. doi: 10.5853/jos.2017.01578. Epub 2018 Jan 31.

低收入和中等收入国家急性缺血性卒中管理的低成本替代方案。

Low-cost alternatives for the management of acute ischemic stroke in low and middle-income countries.

作者信息

Nepal Gaurav, Yadav Jayant Kumar, Bhandari Siddhartha, Gautam Jeevan, Gajurel Bikram Prasad

机构信息

Department of Internal Medicine, Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, 44600, Nepal.

Department of Neurology, Maharajgunj Medical Campus, Tribhuvan University Institute of Medicine, Kathmandu, 44600, Nepal.

出版信息

Ann Med Surg (Lond). 2021 Oct 21;72:102969. doi: 10.1016/j.amsu.2021.102969. eCollection 2021 Dec.

DOI:10.1016/j.amsu.2021.102969
PMID:34992776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8712992/
Abstract

Acute ischemic stroke (AIS) patients arriving within a suitable time frame are treated with recanalization therapy i.e. intravenous thrombolysis (IVT) with alteplase and/or mechanical thrombectomy (MT). IVT with alteplase is indicated in AIS patients presenting within 4.5 hours of onset regardless of vascular territory involved. MT is indicated in AIS patients presenting within 24 hours of onset with large vessel occlusion in the anterior circulation. However, MT is ludicrously expensive and requires exorbitant setup, devices, and expertise which is not currently feasible in LMICs. Therefore, in LMICs the only feasible recanalization option left for AIS patients is IVT. The cost of IVT varies across the LMICs, however, most of them cost around 2000-5000 USD. Apart from IVT, patients with AIS often have other significant medical costs including those for neuroimaging, intensive care, and prolonged rehabilitative treatment. In LMICs, these costs can only be afforded by a handful of patients. The majority of the LMICs have health insurance in their infancy and family members of AIS patients opt-out IVT due to the economic burden. In general, the current treatment guidelines for AIS are not very useful in LMICs because of cost-related issues among several other factors. In this editorial, we discuss evidence for alternative treatment strategies that can help tackle the rising epidemic of AIS in poor countries by improvising on existing clinical guidelines and seeking alternative treatment regimens.

摘要

在合适时间范围内抵达的急性缺血性卒中(AIS)患者接受再灌注治疗,即使用阿替普酶进行静脉溶栓(IVT)和/或机械取栓(MT)。无论涉及哪个血管区域,在发病4.5小时内就诊的AIS患者都可使用阿替普酶进行IVT。MT适用于前循环大血管闭塞且在发病24小时内就诊的AIS患者。然而,MT极其昂贵,需要高昂的设备、装置和专业技术,这在低收入和中等收入国家(LMICs)目前并不可行。因此,在LMICs中,AIS患者唯一可行的再灌注选择是IVT。IVT的费用在不同的LMICs有所不同,不过大多数费用在2000 - 5000美元左右。除了IVT,AIS患者通常还有其他重大医疗费用,包括神经影像学、重症监护和长期康复治疗的费用。在LMICs中,只有少数患者能够承担这些费用。大多数LMICs的医疗保险尚处于起步阶段,AIS患者的家属因经济负担而选择不进行IVT。总体而言,由于成本相关问题以及其他几个因素,目前的AIS治疗指南在LMICs中并不是非常有用。在这篇社论中,我们讨论了替代治疗策略的证据,这些策略可以通过改进现有临床指南和寻求替代治疗方案,帮助应对贫困国家中不断上升的AIS流行趋势。